|Other Accession||NP_005205.2, NP_001032720.1|
|Other Names||Cytotoxic T-lymphocyte protein 4, Cytotoxic T-lymphocyte-associated antigen 4, CTLA-4, CD152, CTLA4, CD152|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Inhibitory receptor acting as a major negative regulator of T-cell responses. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28.|
|Cellular Location||Cell membrane; Single-pass type I membrane protein Note=Exists primarily an intracellular antigen whose surface expression is tightly regulated by restricted trafficking to the cell surface and rapid internalisation;|
|Tissue Location||Widely expressed with highest levels in lymphoid tissues. Detected in activated T-cells where expression levels are 30- to 50-fold less than CD28, the stimulatory coreceptor, on the cell surface following activation|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
CTLA4 is a member of the immunoglobulin superfamilyand encodes a protein which transmits an inhibitory signal to Tcells. The protein contains a V domain, a transmembrane domain, anda cytoplasmic tail. Alternate transcriptional splice variants,encoding different isoforms, have been characterized. Themembrane-bound isoform functions as a homodimer interconnected by adisulfide bond, while the soluble isoform functions as a monomer.Mutations in this gene have been associated with insulin-dependentdiabetes mellitus, Graves disease, Hashimoto thyroiditis, celiacdisease, systemic lupus erythematosus, thyroid-associatedorbitopathy, and other autoimmune diseases.
Liu, Y., et al. Hum. Immunol. 71(11):1141-1146(2010)Andersen, M.K., et al. Diabetes Care 33(9):2062-2064(2010)Azarpira, N., et al. Exp Clin Transplant 8(3):210-213(2010)Liu, G., et al. Nan Fang Yi Ke Da Xue Xue Bao 30(8):1838-1840(2010)Oaks, M.K., et al. Cell. Immunol. 201(2):144-153(2000)
If you have any additional inquiries please email technical services at email@example.com.